Kymera Therapeutics (KYMR) Other Working Capital Changes (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Other Working Capital Changes data on file, last reported at -$1.4 million in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$1.4 million, up 51.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.6 million (up 91.68% YoY), and the FY2025 annual result was -$5.0 million, up 87.72% from the prior year.
• Other Working Capital Changes declined to -$1.4 million in Q1 2026 per KYMR's latest filing, from -$1.3 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $16.8 million in Q3 2022 and troughed at -$44.1 million in Q4 2024.
• A 5-year average of -$5.5 million and a median of -$358000.0 in 2023 frame the typical range for Other Working Capital Changes.
• On a YoY basis, Other Working Capital Changes climbed as much as 917.91% in 2022 and fell as far as 8472.99% in 2022.
• A 5-year view of Other Working Capital Changes shows it stood at -$37.0 million in 2022, then soared by 129.37% to $10.9 million in 2023, then slumped by 505.62% to -$44.1 million in 2024, then surged by 96.99% to -$1.3 million in 2025, then decreased by 2.18% to -$1.4 million in 2026.
• Business Quant data shows KYMR's Other Working Capital Changes at -$1.4 million in Q1 2026, -$1.3 million in Q4 2025, and -$1.3 million in Q3 2025.